

### **REMARKS**

#### ***Remaining Claims***

Claims 1 and 6 have been amended to more clearly point out and distinctly claim the invention. After these amendments are entered, eight (8) claims (Claims 1-8) remain pending in this application through this Amendment.

#### ***Specification objection***

The informality object of the specification has been overcome by the amendment of the paragraph starting at page 1, line 29 and ending at page 4, line 6.

#### ***Rejections under 35 U.S.C. §112***


The rejections, under 35 U.S.C. §112, the second paragraph, of Claims 1 and 5-8 have been overcome by the amendments of claims made through this Amendment.

### **CONCLUSION**

In view of the foregoing and in conclusion, Applicants submit that the objections and rejections set-forth in the Office Action have been overcome, and that all pending claims are now in condition for allowance.

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned. Please address all correspondence to Thomas Hoxie, Novartis Corporation, Corporate Intellectual Property, One Health Plaza, Bldg. 430, East Hanover, NJ 07936-1080. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Respectfully submitted,



Jian S. Zhou  
Reg. No. 41,422  
(678) 415-4691

Date: July 14, 2003

Novartis Corporation  
Corporate Intellectual Property  
One Health Plaza, Bldg. 430  
East Hanover, NJ 07936-1080